TT 038
Latest Information Update: 28 Sep 2024
At a glance
- Originator Teon Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer; Triple negative breast cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 28 Sep 2024 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA
- 28 Aug 2020 Teon Therapeutics plans to file an IND application for prospective clinical development in Prostate cancer and Breast cancer (Teon Therapeutics pipeline, August 2020)